

X15648  
BA



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number: **0 322 094 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

- (45) Date of publication of patent specification: **02.12.92** (51) Int. Cl.<sup>5</sup>: **A61K 37/02, C12N 15/00, C12N 1/18, C12P 21/02, //C12N5/00**  
(21) Application number: **88310000.0**  
(22) Date of filing: **25.10.88**

(54) **N-terminal fragments of human serum albumin.**

- (30) Priority: **30.10.87 GB 8725529**  
(43) Date of publication of application: **28.06.89 Bulletin 89/26**  
(45) Publication of the grant of the patent: **02.12.92 Bulletin 92/49**  
(84) Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**  
(56) References cited:  
**EP-A- 0 073 646**  
**EP-A- 0 201 239**

**THE BIOCHEMICAL JOURNAL**, vol. 163, no. 3, 1977, pages 477-484, GB; M.J. GEISOW et al.: "Physical and binding properties of large fragments of human serum albumin"

**THE JOURNAL OF BIOLOGICAL CHEMISTRY**, vol. 257, no. 6, 25th March 1982, pages 2770-2774, US; N. DOYEN et al.: "Immunochemical cross-reactivity between cyanogen bromide fragments of human serum albumin"

- (73) Proprietor: **Delta Biotechnology Limited**  
**Castle Court, Castle Boulevard**  
**Nottingham NG7 1FD(GB)**  
(72) Inventor: **Ballance, David James**  
**11 South Road**  
**West Bridgford Nottingham NG2 7AG(GB)**  
Inventor: **Hinchliffe, Edward**  
**16 Lambley Lane**  
**Burton Joyce Nottingham NG14 5BG(GB)**  
Inventor: **Geisow, Michael John**  
**115 Main Street**  
**East Bridgford Nottingham NG13 8NH(GB)**  
Inventor: **Senior, Peter James**  
**Wilson House Wilson**  
**Near Melbourne Derbyshire(GB)**  
(74) Representative: **Bassett, Richard Simon et al**  
**ERIC POTTER & CLARKSON St Mary's Court**  
**St Mary's Gate**  
**Nottingham NG1 1LE(GB)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**EP 0 322 094 B1**

## Description

This invention relates to a novel polypeptide molecule which can be produced by recombinant DNA technology and can be used for many of the existing applications of human serum albumin.

Human serum albumin (HSA) is the most abundant plasma protein, contributing 60% w/w of the total protein content of the plasma. A molecule of HSA consists of a single non-glycosylated polypeptide chain of 585 amino acids of formula molecular weight 66,500. The amino acid sequence of HSA has been established by protein sequence analysis (Meloun et al, 1975, "Complete amino acid sequence of human serum albumin" FEBS. Letters: 58:1, 136-317; Behrens et al, 1975, "Structure of human serum albumin" Fed. Proc. 34, 591) and more recently by genetic analysis (Lawn et al, 1981, Nucleic Acids Research 9, 6102-6114). Although there have been discrepancies between the amino acid sequences as published (some being attributable to polymorphisms), Figure 1 represents the amino acid sequence currently believed to be most representative of the HSA present within the human population.

Because of its relatively small molecular weight and net negative charge at physiological pH (Peters, 1970, "Serum albumin", Adv. Clin. Chem. 13, 37-111), HSA contributes 85% of the osmotic effect of normal plasma. Thus HSA is the principal regulator of plasma volume. A secondary role of HSA is to bind small molecules produced by catabolic processes (for example fatty acids and bilirubin). Albumin represents the principal means for the transport of these key metabolites, which are poorly soluble at physiological pH. Physical, chemical, immunological and limited proteolytic studies of HSA have shown that the molecule is composed of regions of polypeptide chains which retain their conformation after separation from the parent molecule by enzymatic means. These polypeptide chains retain their binding capabilities thereby facilitating the mapping of binding sites for bilirubin, fatty acids and other small molecules to particular regions of the polypeptide chain (Kragh-Hansen, 1981, "Molecular aspects of ligand binding to serum albumin". A. Soc. Pharm. Expt. Ther. 33, 1, 17-53). Much of the information in this area has been reviewed (Brown and Shockley, 1982, "Serum albumin: structure and characterisation of its ligand binding sites").

The indications for the clinical use of therapeutic concentrates of HSA are related principally to its oncotic action as a plasma volume expander. Concentrates of HSA have been used therapeutically since the 1940's, in particular in cases of shock, burns, adult respiratory distress syndrome, and cardiopulmonary bypass. Albumin has also been used in cases of acute liver failure, following removal of ascitic fluid from patients with cirrhosis, after surgery, in acute nephrosis, in renal dialysis, and as a transport protein for removing toxic substances, such as in severe jaundice in haemolytic disease of the new born.

In addition to its use as a therapeutic agent, HSA is a major component of serum added to media used to support the growth of mammalian cells in tissue culture. The consumption of serum and hence of albumin has been greatly increased over recent years as biotechnology and pharmaceutical companies have expanded their tissue culture for research and for production. There is a universal need for lower cost and better regulation of sera for these purposes.

It is known to manipulate the HSA-encoding DNA sequence express a recombinant polypeptide in microorganisms. Indeed such a recombinant HSA polypeptide has been produced in bacterial species such as *Escherichia coli* (G.B. Patent No. 2 147 903B) and *Bacillus subtilis* (European Patent Application No. 86304656.1) and the yeast *Saccharomyces cerevisiae* (European Patent Publication No. 201 239, Delta Biotechnology Ltd.); thus it is generally accepted that a recombinant polypeptide essentially identical to natural HSA can be produced in a variety of microbial hosts by employing known methods. However, in all cases where recombinant HSA has been produced, the objective has been to produce a molecule which is "nature-identical" to HSA in structure and biological function.

It has now been found that it is advantageous to produce shorter forms of HSA.

One aspect of the present invention provides a polypeptide comprising the N-terminal portion of human serum albumin up to amino acid residue n, where n is 369 to 419, and variants thereof, but excluding HSA (1-387).

The novel polypeptides of the invention are hereinafter referred to as "HSA(1-n)".

The term "human serum albumin" is intended to include (but not necessarily to be restricted to) known or yet-to-be-discovered polymorphic forms of HSA. For example, albumin Naskapi has Lys-372 in place of Glu-372 and pro-albumin Christchurch has an altered pro-sequence. The term "variants" is intended to include (but not necessarily to be restricted to) minor artificial variations in residues 1 to n (such as molecules lacking one or a few residues, having conservative substitutions or minor insertions of residues, or having minor variations of amino acid structure). Thus polypeptides which have 80%, preferably 85%, 90%, 95% or 99%, homology with any HSA (1-n) compound are deemed to be "variants". Such variants are preferably 360 to 430 amino acids long, more preferably 369 to 419 amino acids long and most preferably 386 to 388 amino acids long. "Variants" furthermore have useful levels of oncotic activity in use.

Furthermore, any putative variant which is to be used pharmacologically should be non-immunogenic in the animal (especially human) being treated.

Conservative substitutions are those where one or more amino acids are substituted others having similar properties such that one skilled in the art of polypeptide chemistry would expect at least the secondary structure, and preferably the tertiary structure, of the polypeptide to be substantially unchanged. For example, typical such substitutions include alanine or valine for glycine, arginine or asparagine for glutamine, serine for asparagine and histidine for lysine. Variants may alternatively, or as well, lack up to ten (preferably only one or two) amino acid residues in comparison with any given HSA (1-n); preferably any such omissions occur in the 100 to 369 portion of the molecule (relative to mature HSA itself). Similarly, up to ten, but preferably only one or two, amino acids may be added, again in the 100 to 369 portion for preference. The term "physiologically functional equivalents" also encompasses larger molecules comprising the said 1 to n sequence plus a further sequence at the N-terminal (for example, pro-HSA(1-n), pre-pro-HSA(1-n), met-HSA(1-n), and HSA(1-n) having a suitable leader sequence which is not necessarily native to HSA).

If the HSA (1-n) is to be prepared by culturing a transformed yeast (*S. cerevisiae*) as is described in more detail below, the leader sequence may, for example, be that found naturally with the yeast alpha-factor protein. C-terminal fusion products with other polypeptides of interest may be produced. Known forms and fragments of HSA are clearly to be regarded as excluded from the above definition, for example HSA(1-387), which was a peptic fragment produced in low yield (Geisow and Beaven, *Biochem. J.* 161. 619-624, 1977 and *ibid.* 163, 477-484, 1977. These prior articles identify the fragment as 1-386, but it has since become apparent (see, for example, Lawn et al, *op-cit.*) that this is due to the authors' use of incorrect published sequence information and that the fragment was in fact 1-387). Similarly, a C-terminal fusion protein comprising HSA (1-n) and the remaining HSA residues (numbers n + 1 to 585) is not claimed as part of the invention.

Particularly preferred novel HSA(1-n) compounds include HSA(1-373) (i.e. C-terminal Val), HSA(1-388) (i.e. C-terminal Ile), HSA(1-389) (i.e. C-terminal Lys), HSA(1-390) (i.e. C-terminal Gln) and HSA(1-407) (i.e. C-terminal Leu).

The HSA(1-n) molecules are preferably produced by means for recombinant DNA technology (optionally followed by proteolytic digestion), rather than by chemical or enzymatic degradation of natural HSA, or by peptide synthesis. In the case of enzymatic degradation, for example, a trypsin-like enzyme will cleave HSA between Lys(389) and Gln(390) but also concomitantly at other cleavage sites. In the future, peptide synthesis may become more feasible for molecules as long as 419 amino acids, but at present is not a practical proposition. Expression in yeast is particularly preferred.

It has been found that, at least in some situations where the HSA(1-n) compound is produced by culturing a transformed host, some HSA(1-n) compounds which are longer than HSA(1-387) are proteolytically digested back to HSA (1-387) by the enzymes which are naturally present in the system. Thus, one can, if desired, use a nucleotide sequence corresponding to a given HSA(1-n) compound in order to prepare another HSA(1-n) compound.

The new molecules herein described can be used as an effective substitute for either natural HSA or nature-identical recombinant HSA as a plasma volume expander. An advantage of HSA(1-n) over natural HSA and recombinant nature-identical HSA relates to the efficacy of raising the colloid osmotic pressure of blood. The smaller molecular weight (approximately 44 kilo-daltons) of the protein of the present invention means that an individual protein dose of only one-half to two-thirds that of natural-HSA or nature-identical recombinant HSA will be required for the equivalent colloid osmotic effect. Consequently, any process for the production of this novel polypeptide by means of recombinant DNA technology may afford significant economic advantages over known processes for the production of nature-identical recombinant HSA, since substantially less proteinaceous material is required to be produced for an effective dose.

Thus, a second aspect of the invention provides a pharmaceutical composition comprising HSA(1-n)-plus, where HSA(1-n)plus is HSA(1-n) as defined above or any HSA(1-n) molecules which are known per se but have not been proposed for pharmaceutical use.

HSA (1-387) which, as discussed above, was a fragment produced by chance in a prior art peptic digest of HSA, is particularly preferred as the HSA(1-n) plus in such a pharmaceutical composition. The composition may comprise "variants" of HSA (1-387) as defined above.

A third aspect provides a method of treating a human for shock, burns or other conditions in which albumin is indicated, comprising administering intravenously a blood-bulking or blood-clearing effective non-toxic amount of a sterile non-pyrogenic solution of a polypeptide comprising HSA(1-n) plus.

Further aspects of the invention include (a) vectors, plasmids and transformed microorganisms, including cell lines, encoding HSA(1-n)plus expression; (b) processes for the production of HSA(1-n)plus

comprising the fermentation under suitable conditions of a microorganism (including a cell line) so transformed as to express HSA(1-n)plus; and (c) laboratory media comprising HSA(1-n)plus.

A further advantage of at least some HSA(1-n) plus molecules over nature-identical recombinant HSA is that their smaller size and thus reduced amino acid content has been found to lead to an increase in the yield obtained (molecules per cell dry weight) in microbial hosts relative to that obtained currently for nature-identical recombinant HSA. Thus, not only has it been found that the scale of the process can be reduced, but also productivity in the recombinant host organism can be enhanced.

The compounds of the invention may be used as blood-bulking (plasma-expanding) agents in analogous ways and in analogous formulations as HSA itself except that the dose of the HSA(1-n)plus compound (in terms of weight) will generally be less than that of HSA as the oncotic effect of the former is greater. The pharmacist or clinician skilled in the art will readily be able to determine by routine and non-inventive experimentation the optimum dose of the HSA(1-n)plus compound. Generally, the amount of HSA(1-n)plus which is administered will be about two-thirds of the amount of HSA which would be administered.

HSA (1-n) plus compounds may also be used as:

(1) substitutes for HSA or, more commonly, bovine serum albumin (BSA) in tissue culture media, thereby reducing the risk of contamination of the medium with, for example, viruses and mycoplasmas; (2) substitutes for BSA in the stationary phase in liquid chromatography for resolution of enantiomers and so on.

## EXAMPLES

The invention will now be illustrated by way of example and with reference to the drawings, in which:

Figure 1 depicts the amino acid sequence currently thought to be the most representative of natural HSA, with (boxed) the alternative C-terminal of HSA(1-n);

Figure 2 depicts the DNA sequence coding for mature HSA;

Figure 3 illustrates, diagrammatically, the construction of mHOB16;

Figure 4 illustrates, diagrammatically, the construction of pHOB31; and

Figure 5 is a copy of a rocket electrophoretogram showing the increased yield of HSA(1-389) over complete HSA.

Standard recombinant DNA procedures are as described by Maniatis et al (1982) unless otherwise stated. Construction and analysis of M13 recombinant clones was as described by Messing (1983) and Sanger et al. (1977).

The human serum albumin coding sequence used in the construction of the following molecules is derived from the plasmid M13mp19.7 (European Patent Application No. 201 239, Delta Biotechnology Ltd.) or by synthesis of oligonucleotides equivalent to parts of this sequence. Oligonucleotides were synthesised using phosphoramidite chemistry on an Applied Biosystems 380B oligonucleotide synthesizer according to the manufacturer's recommendations (AB Inc., Warrington, Cheshire, England).

### Example 1: HSA (1-389)

An expression vector was constructed in which DNA encoding the HSA secretion signal and mature HSA up to and including the 389th amino acid, lysine, was placed downstream of the *S.cerevisiae* phosphoglycerate kinase gene (PGK) promoter and followed by a stop codon and the PGK terminator of transcription. This vector was then introduced into *S.cerevisiae* by transformation and directed the expression and secretion from the cells of a molecule representing the N-terminal 389 amino acids of HSA.

An oligonucleotide was synthesised (Linker 1) which represented a part of the known HSA coding sequence (Figure 2) from the PstI site (1092, Figure 2) to the codon for valine 381 wherein that codon was changed from GTG to GTC:

Linker 1

D P H E C Y A K V F D E  
 5' GAT CCT CAT GAA TGC TAT GCC AAA GTG TTC GAT GAA  
 5 3' ACGT CTA GGA GTA CTT ACG ATA CGG TTT CAC AAG CTA CTT  
 1100 1120  
 F K P L V  
 10 TTT AAA CCT CTT GTC 3'  
 AAA TTT GGA GAA CAG 5'

15 Linker 1 was ligated into the vector M13mp19 (Norlander et al, 1983) which had been digested with PstI and HincII and the ligation mixture was used to transfect E.coli strain XL1-Blue (Stratagene Cloning Systems, San Diego, CA). Recombinant clones were identified by their failure to evolve a blue colour on medium containing the chromogenic indicator X-gal (5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactoside) in the presence of IPTG (isopropylthio- $\beta$ -galactoside). DNA sequence analysis of template DNA prepared from  
 20 bacteriophage particles of recombinant clones identified a molecule with the required DNA sequence, designated mHOB12 (Figure 3).

M13mp19.7 consists of the coding region of mature HSA in M13mp19 (Norlander et al, 1983) such that the codon for the first amino acid of HSA, GAT, overlaps a unique XhoI site thus:

25  
 Asp Ala  
 5' C T C G A G A T G C A 3'  
 30 3' G A G C T C T A C G T 5'  
 XhoI

(EPA No. 210239 A1). M13mp19.7 was digested with XhoI, made flush-ended by S1-nuclease treatment  
 35 and was then ligated with the following oligonucleotide (Linker 2):

Linker 2

40 5' T C T T T T A T C C A A G C T T G G A T A A A A G A 3'  
 3' A G A A A A T A G G T T C G A A C C T A T T T T C T 5'  
 HindIII

45 The ligation mix was then used to transfect E.coli XL1-Blue and template DNA was prepared from several plaques and then analysed by DNA sequencing to identify a clone, pDBD1 (Figure 4), with the correct sequence.

50 A 1.1 kb HindIII to PstI fragment representing the 5' end of the HSA coding region and one half of the inserted oligonucleotide linker was isolated from pDBD1 by agarose gel electrophoresis. This fragment was then ligated with double stranded mHOB12 previously digested with HindIII and PstI and the ligation mix was then used to transfect E.coli XL1-Blue. Single stranded template DNA was prepared from mature bacteriophage particles of several plaques. The DNA was made double stranded in vitro by extension from  
 55 annealed sequencing primer with the Klenow fragment of DNA polymerase I in the presence of deoxynucleoside triphosphates. Restriction enzyme analysis of this DNA permitted the identification of a clone with the correct configuration, mHOB15 (Figure 4).

The following oligonucleotide (Linker 3) represents from the codon for the 382nd amino acids of mature

HSA (glutamate, GAA) to the codon for lysine 389 which is followed by a stop codon (TAA) and a HindIII site and then a BamHI cohesive end:

#### Linker 3

5

```

      E   E   P   Q   N   L   I   K   J
5'   GAA GAG CCT CAG AAT TTA ATC AAA TAA GCTTG      3'
10  3'   CTT CTC GGA GTC TTA AAT TAG TTT ATT CGAACCTAG      5'

```

This was ligated into double stranded mHOB15, previously digested with HincII and BamHI. After ligation, the DNA was digested with HincII to destroy all non-recombinant molecules and then used to transfect E.coli XL1-Blue. Single stranded DNA was prepared from bacteriophage particles of a number of clones and subjected to DNA sequence analysis. One clone having the correct DNA sequence was designated mHOB16 (Figure 4).

A molecule in which the mature HSA coding region was fused to the HSA secretion signal was created by insertion of Linker 4:

#### Linker 4

```

      M   K   W   V   S   F   I   S   L   L   F   L
25  5' GATCC ATG AAG TGG GTA AGC TTT ATT TCC CTT CTT TTT CTC
      G TAC TCC ACC CAT TCG AAA TAA AGG GAA GAA AAA GAG
30
      F   S   S   A   Y   S   R   G   V   F   R   R
      TTT AGC TCG GCT TAT TCC AGG GGT GTG TTT CG      3'
      AAA ACG AGC CGA ATA AGG TCC CCA CAC AAA GCAGCT      5'
35

```

into BAMHI and XhoI digested M13mp19.7 to form pDBD2 (Figure 5). In this linker the codon for the fourth amino acid after the initial methionine, ACC for threonine in the HSA pre-pro leader sequence (Lawn et al, 1981), has been changed to AGC for serine to create a HindIII site.

The 5' end of this construction was removed as a BamHI to PvuII fragment and ligated with the PvuII to BamHI fragment of double stranded mHOB16 (representing the 3' end of the truncated HSA gene) into pMA91 (Mellor et al, 1983) at the BglII site to form pHOB31 (Figure 4). This molecule contains the truncated HSA coding region with the HSA secretion signal between the S.cerevisiae PGK gene promoter and terminator such that the 5' end of the gene abuts the promoter. The molecule also contains a selectable marker for yeast transformation, LEU2, and part of the yeast 2um plasmid to permit autonomous replication in yeast.

The plasmid pHOB31 was introduced into S.cerevisiae AH22 (Hinnen et al, 1978) by transformation using standard procedures (Beggs, 1978). Purified transformants were grown in YEPD broth (1% yeast extract, 2% peptone, 2% glucose) for 3 days at 30°C and the culture supernatant was then analysed, successfully, for the presence of HSA-related material by rocket gel electrophoresis. Figure 5 shows the electrophoretogram: the yield of HSA-related material from transformants harbouring a plasmid encoding HSA(1-389) is demonstrably higher than the yield from a transformant secreting mature, natural, HSA.

However, production of HSA (1-389) gave a product indistinguishable from HSA (1-387) (see Example 2) by both amino-terminal and carboxy-terminal sequence analysis. This is probably explained by the efficient removal of the COOH-terminal sequence Ile-Lys.

#### EXAMPLE 2: HSA (1-387)

The construction of a plasmid encoding HSA (1-387) was identical to the procedure for construction of the HSA (1-389) plasmid, pHOB31, except that the linker 3 was substituted by linker 5 (shown below) which represents the region from the codon for the 382nd amino acid of mature HSA (glutamate, GAA) to the codon for leucine 387 which is followed by a stop codon and a HindIII site and then a BamHI cohesive end:

#### Linker 5

```

      E   E   P   Q   N   L   Stop
10  5'  GAA GAG CCT CAG AAT TTA TAA GCTTG      3'
      3'  CTT CTC GGA GTC TTA AAT ATT CGAACCTAG 5'

```

The remainder of the construction was as detailed above for pHOB31 and resulted in the plasmid pDBD5.

#### EXAMPLE 3: (1-369)

In order to construct a plasmid encoding HSA (1-369), a linker was synthesised representing the region from the PstI site of mature HSA (position 1092, Figure 3) to the codon for cystine 369 which was followed by a stop codon (TAA), a HindIII site and then a BamHI cohesive end:

#### Linker 6

```

      D   P   H   E   C   Stop
25  5'      GAT CCT CAT GAA TGC TAA GCTTG
      3'  A CGT CTA GGA GTA CTT ACG ATT CGAACCTAG
30

```

This linker was ligated with the BamHI PstI fragment of pDBD2, representing the 5' part of preproHSA, into pMA91 at the BglII site. A plasmid with the correct configuration was termed pDBD3 (Figure 6).

Production of HSA (1-369) by culturing S.cerevisiae transformed with pDBD3 gave low yields, indicating that the product may have been unstable in the yeast expression system used.

#### EXAMPLE 4: HSA (1-419)

For the construction of a plasmid encoding HSA (1-419) the BamHI - HincII fragment of pDBD2 was ligated with an annealed self-complementary oligonucleotide (linker 7):

#### Linker 7

```

45  5' ATAAGCTTGGATCCAAGCTTAT 3'

```

and then the ligation mix was digested with BamHI and the fragment was ligated into pMA91 to give pDBD4 (Figure 7). In this construct the HincII site (1256, Figure 3) of pDBD2 creates a blunt end after the second base of the codon for serine 419 and this codon is reformed by the linker 6 such that this codon is followed by a stop codon, a HindIII site and a BamHI site.

Expression of HSA (1-419) via plasmid pDBD5 in S.cerevisiae produced a molecule with the correct amino terminal sequence (Asp-Ala-His.....) but leucine and not serine was the COOH-terminal residue. Attempts to isolate the COOH-terminal peptide using a covalent label which should attach to cysteine 392 also were unsuccessful. It was concluded that proteolysis of part of the COOH-terminus of HSA (1-419) occurred. This is consistent with the observation of a small percentage of proteolysis in the same position of full-length HSA produced in an analogous manner in yeast (Sleep et al. 1988).

#### EXAMPLE 5: Fermentation of HSA(1-n)plus-producing yeast

A laboratory fermenter is filled to half its nominal working volume with an initial "batch" medium containing 50ml/l of a salts mixture (containing 114g/l  $\text{KH}_2\text{PO}_4$ , 12g/l  $\text{MgSO}_4$ , 3.0g/l  $\text{CaCl}_2 \cdot 6\text{H}_2\text{O}$ , 2.0g/l  $\text{Na}_2\text{EDTA}$ : 10ml/l of a trace elements solution containing 3g/l  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ , 10g/l  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ , 3.2g/l  $\text{MnSO}_4 \cdot 4\text{H}_2\text{O}$ , 79mg/l  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , 1.5g/l  $\text{H}_3\text{BO}_3$ , 0.2g/l  $\text{KI}$ , 0.5g/l  $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ , 0.56g/l  $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ , 75ml/l  $\text{H}_3\text{PO}_4$ : 20g/l sucrose: 50ml/l of a vitamins mixture containing 1.6g/l Ca pantothenate, 1.2g/l nicotinic acid, 12.8g/l m inositol, 0.32g/l thiamine HCl and 8mg/l pyridoxine HCl and 8mg/l biotin. An equal volume of "feed" medium containing 100ml/l of the salts mixture, 20ml/l of trace elements solution 500g/l sucrose and 100ml/l vitamin solution is held in a separate reservoir connected to the fermenter by a metering pump.

The fermenter is inoculated with *Saccharomyces cerevisiae* which has been transformed as above with plasmid pDBD3 from Example 2. The pH is maintained at  $5.7 \pm 0.2$  by automatic addition of ammonia or sulphuric acid, the temperature is kept at  $30^\circ\text{C}$  and the stirred speed is adjusted to give a dissolved oxygen tension (DOT) of  $> 20\%$  air saturation at 1 v/v/min air flow rate. When the initial substrate has been consumed, the metering pump is turned on, maintaining a growth rate of approximately  $0.15\text{h}^{-1}$ . The pump rate is increased to maintain this growth rate until the stirrer speed reached its maximum value at which point it is not possible to increase the pump rate any further without causing the DOT to fall below 15% air saturation which is the minimum value permitted to occur. PPG 2000 is added in response to a foam sensor. None is added until over 50% of the feed solution had been added. The final level of addition is 0.2g/l.

HSA(1-387) is secreted into the medium

#### EXAMPLE 6: Binding of bilirubin to HSA(1-387)

Binding of the haem metabolite, bilirubin, to HSA (1-387) was carried out by a fluorescence enhancement method (Beaven and Gratzen (1973) Eur. J. Biochem. 33, 500-510). Figure 8 shows that the enhancement of bilirubin fluorescence as a function of protein/bilirubin ratio is indistinguishable for HSA(1-387) and clinical grade HSA.

The interaction of HSA and bilirubin is very sensitive to the conformation of the protein (Beaven and Gratzen, loc. cit.) and these results indicate that no gross alteration in conformation of the regions of HSA represented by HSA(1-387) has occurred through the expression of a shorter molecule.

#### EXAMPLE 7: Oncotic behaviour of HSA(1-387)

HSA(1-387) was concentrated in 0.9% w/v saline to a final protein concentration of 54 mg/ml. Dilutions of this concentrate, together with dilutions of a clinical grade HSA (100 mg/ml), were compared for osmotic effect in a colloid osmometer. Figure 9 indicates that HSA(1-387) gives a colloid osmotic pressure approximately one-third higher than that of full-length HSA at a given protein concentration. Importantly, the increase in colloid osmotic pressure with protein concentration is approximately linear over a range up to 5% w/v, which represents the concentration in plasma.

This indicates that HSA(1-387) does not self-associate appreciably within a useful working clinical concentration range.

#### EXAMPLE 8: Formulations for Injection

The HSA(1-n)plus of the invention may be presented in container sizes ranging from 20ml to 500ml, with the concentration thereof varying (typically) from 2% to 17%, for example 3%, 13% or 17%.

The solution for administration is sterile and pyrogen free. A 3% solution is osmotically similar to human plasma. At least 96% of the total protein is preferably albumin. The sodium ion content is generally between 130-160mmol/litre and the potassium ion content is generally not more than 2mmol/litre. The pH is adjusted to  $6.9 \pm 0.5$ . The concentration of citrate is generally no more than 20mmol/litre and may be absent altogether.

Stabilizers may be used, for example either 0.16 millimole sodium acetyl tryptophanate, or 0.08 millimole sodium acetyl tryptophanate and 0.08 millimole sodium caprylate per gram of HSA(1-n)plus.

#### References

- Beggs, J.D. (1978). Nature. 275, 104-109.  
Brown, J.R. and Shockley, P., (1982) in "Lipid-Protein Interactions" 1, 25-68. Eds. Hayes, O. and Jost, P.C.  
Hinnen, A. et al (1978). Proc. Natl. Acad. Sci. USA, 75, 1929-1933.



- Lawn, R.M. et al (1981). Nucl. Acid. Res. 9, 6103-6114.  
 Maniatis, T. et al (1982). Molecular cloning: A laboratory manual. Cold Spring Harbour Laboratory, Cold Spring Harbor, New York.  
 Mellor, J. et al (1983). Gene, 24, 1-14.  
 5 Messing, J. (1983). Methods Enzymol. 101, 20-78.  
 Norrander, J. et al (1983). Gene, 26, 101-106.  
 Sanger, F. et al (1977). Proc. Natl. Acad. Sci. USA, 74, 5463-5467.  
 Sleep, D. Belfield, G.P. and Goodey, A.R. (1988) Yeast 4, S168.

## 10 Claims

1. A polypeptide comprising the N-terminal portion of mature human serum albumin up to amino acid residue n, where n is 369 to 419, or a variant thereof, which variants have at least 80% homology with the said N-terminal portion and have a useful level of oncotic potential when administered into the bloodstream of a mammal, but excluding the said N-terminal portion where n is 387.
2. A polypeptide according to Claim 1 wherein the polypeptide is selected from the group consisting of HSA (1-373), HSA (1-388), HSA (1-389), HSA (1-390) and HSA (1-407) and variants thereof, such variants fulfilling the said two criteria.
3. A pharmaceutical composition comprising a polypeptide comprising the N-terminal portion of mature human serum albumin up to amino acid residue n, where n is 369 to 419, or a variant thereof, which variants have at least 80% homology with the said N-terminal portion and have a useful level of oncotic potential when administered into the bloodstream of a mammal.
4. A composition according to Claim 3 wherein the polypeptide is HSA (1-387) or a said variant thereof.
5. A nucleotide sequence encoding a polypeptide comprising the N-terminal portion of mature human serum albumin up to amino acid residue n, where n is 369 to 419, or a polypeptide variant thereof which has at least 80% homology with the said N-terminal portion and a useful level of oncotic potential when administered into the bloodstream of a mammal, the nucleotide sequence not being linked at its 3' end to a further sequence encoding the C-terminal portion of mature human serum albumin from amino acid residue n + 1 to 585.
6. A nucleotide sequence according to Claim 5 wherein n is 387.
7. A nucleotide sequence according to Claim 5 or 6 linked at its 5' end to a further nucleotide sequence encoding a peptide corresponding to the pro-, pre-, or pre-pro- position of HSA, a methionine residue, or another leader sequence.
8. An expression vector suitable for transformation of and expression in a selected host, the vector comprising a nucleotide sequence according to any one of Claims 5 to 7 and the said nucleotide sequence being a DNA sequence.
9. A host organism transformed with a vector according to Claim 8.
10. A host organism according to Claim 9 which is Saccharomyces cerevisiae.
11. A process for the production of a polypeptide comprising the culture under suitable conditions of a host microorganism according to Claim 9 or 10, the said polypeptide being encoded by the said nucleotide sequence.
12. A laboratory medium for the growth of microorganisms comprising a polypeptide comprising the N-terminal portion of mature human serum albumin up to amino acid residue n, where n is 369 to 419, or a variant thereof, which variants have at least 80% homology with the said N-terminal portion and have a useful level of oncotic potential when administered into the bloodstream of a mammal.
13. A medium according to Claim 12 wherein n is 387.

**Patentansprüche**

1. Polypeptid, umfassend den N-terminalen Teil von reifem Humanserumalbumin bis zu einem Aminosäurerest n, worin n = 369 bis 419, oder einer Variante desselben, wobei die Varianten mindestens 80% Homologie mit diesem N-terminalen Teil aufweisen und bei Verabreichung in den Blutstrom eines Säugetiers einen geeigneten Grad an onkotischem Potential besitzen, ausschließlich des N-terminalen Teils mit n = 387.
2. Polypeptid nach Anspruch 1, ausgewählt aus der Gruppe HSA (1-373), HSA (1-388), HSA (1-389), HSA (1-390) und HSA (1-407) sowie Varianten desselben, die den genannten beiden Kriterien genügen.
3. Arzneimittel mit einem Polypeptid, umfassend den N-terminalen Teil von reifem Humanserumalbumin bis zu einem Aminosäurerest n, wobei n = 369 bis 419, oder einer Variante desselben, wobei die Varianten mindestens 80% Homologie mit dem N-terminalen Teil aufweisen und bei Verabreichung in den Blutstrom eines Säugetiers einen geeigneten Grad an onkotischem Potential aufweisen.
4. Mittel nach Anspruch 3, wobei das Polypeptid aus HSA (1-387) oder einer genannten Variante desselben besteht.
5. Nukleotidsequenz mit Codierung für ein Polypeptid, umfassend den N-terminalen Teil von reifem Humanserumalbumin bis zu einem Aminosäurerest n, worin n = 369 bis 419, oder einer Polypeptidvariante desselben, die mindestens 80% Homologie mit dem N-terminalen Teil aufweist und bei Verabreichung in den Blutstrom eines Säugetiers einen geeigneten Grad an onkotischem Potential besitzt, wobei die Nukleotidsequenz nicht an seinem 3'-Ende mit einer weiteren Sequenz mit Codierung für den C-terminalen Teil von reifem Humanserumalbumin von einem Aminosäurerest n+1 bis 585 verknüpft ist.
6. Nukleotidsequenz nach Anspruch 5, worin n = 387.
7. Nukleotidsequenz nach Anspruch 5 oder 6, die an ihrem 5'-Ende mit einer weiteren Nukleotidsequenz mit Codierung für ein Peptid entsprechend der Pro-, Prä- oder Prä-Pro-Stellung von HSA, einem Methioninrest oder einer weiteren Leader-Sequenz verknüpft ist.
8. Expressionsvektor mit der Eignung zur Transformation eines und Expression in einem ausgewählten Wirt(s), umfassend eine Nukleotidsequenz nach einem der Ansprüche 5 bis 7, bei der es sich um eine DNS-Sequenz handelt.
9. Mit einem Vektor nach Anspruch 8 transformierter Wirtorganismus.
10. Wirtorganismus nach Anspruch 9, nämlich *Saccharomyces cerevisiae*.
11. Verfahren zur Herstellung eines Polypeptids, umfassend die Züchtung eines Wirtmikroorganismuses nach Anspruch 9 oder 10 unter geeigneten Bedingungen, wobei das Polypeptid durch die Nukleotidsequenz codiert wird.
12. Labormedium für das Wachstum von Mikroorganismen, umfassend ein Polypeptid mit dem N-terminalen Teil von reifem Humanserumalbumin bis zu einem Aminosäurerest n, worin n = 369 bis 419, oder eine Variante desselben, wobei die Varianten mindestens 80% Homologie mit dem N-terminalen Teil aufweisen und bei Verabreichung in den Blutstrom eines Säugetiers einen geeigneten Grad an onkotischem Potential besitzen.
13. Medium nach Anspruch 12, worin n = 387.

**Revendications**

1. Polypeptide comprenant la portion N-terminale de la sérum albumine humaine mature jusqu'au résidu d'acide amine n, où n est 369 à 419, ou d'un variant de celle-ci, lesquels variants présentent au moins 80% d'homologie avec ladite portion N-terminale et présentent un niveau utile de potentiel oncotique

lorsqu'ils sont administrés dans le flux sanguin d'un mammifère, mais à l'exclusion de ladite portion N-terminale où n est 387.

2. Polypeptide selon la revendication 1, dans lequel le polypeptide est choisi dans le groupe constitué par HSA (1-373), HSA (1-388), HSA (1-389), HSA (1-390) et HSA (1-407), et des variants de celles-ci, de tels variants remplissant les deux critères précités.
3. Composition pharmaceutique comprenant un polypeptide comprenant la portion N-terminale de la sérum albumine humaine mature jusqu'au résidu d'acide aminé n, où n est 369 à 419, ou d'un variant de celle-ci, lesquels variants présentent au moins 80% d'homologie avec ladite portion N-terminale et présentent un niveau utile de potentiel oncotique lorsqu'ils sont administrés dans le flux sanguin d'un mammifère.
4. Composition selon la revendication 3, dans laquelle le polypeptide est HSA (1-387) ou un variant précité de celle-ci.
5. Séquence nucléotidique codant pour un polypeptide comprenant la portion N-terminale de la sérum albumine humaine mature jusqu'au résidu d'acide aminé n, où n est 369 à 419, ou d'un variant polypeptidique de celle-ci, qui présente au moins 80% d'homologie avec ladite portion N-terminale et un niveau utile de potentiel oncotique lorsqu'il est administré dans le flux sanguin d'un mammifère, la séquence nucléotidique n'étant pas reliée à son extrémité 3' à une autre séquence codant pour la portion C-terminale de la sérum albumine humaine mature du résidu d'acide aminé n + 1 à 585.
6. Séquence nucléotidique selon la revendication 5, dans laquelle n est 387.
7. Séquence nucléotidique selon l'une des revendications 5 et 6, reliée à son extrémité 5' à une autre séquence nucléotidique codant pour un peptide correspondant à la position pro-, pré-, ou pré-pro- de la HSA, un résidu méthionine, ou une autre séquence leader.
8. Vecteur d'expression approprié pour la transformation et l'expression dans un hôte choisi, le vecteur comprenant une séquence nucléotidique conforme à l'une quelconque des revendications 5 à 7 et ladite séquence nucléotidique étant une séquence d'ADN.
9. Organisme hôte transformé par un vecteur conforme à la revendication 8.
10. Organisme hôte selon la revendication 9, qui est Saccharomyces cerevisiae.
11. Procédé de production d'un polypeptide comprenant la culture dans des conditions appropriées d'un microorganisme hôte conforme à l'une des revendications 9 et 10, ledit polypeptide étant codé par ladite séquence nucléotidique.
12. Milieu de laboratoire pour la croissance de microorganismes comprenant un polypeptide comprenant la portion N-terminale de la sérum albumine humaine mature jusqu'au résidu d'acide aminé n, où n est 369 à 419, ou d'un variant de celle-ci, lesquels variants présentent au moins 80% d'homologie avec ladite portion N-terminale et présentent un niveau utile de potentiel oncotique lorsqu'ils sont administrés dans le flux sanguin d'un mammifère.
13. Milieu selon la revendication 12, dans lequel n est 387.

Fig. 2.

Asp	Ala	His	Lys	Ser	Glu	Val	Ala	His	Arg	Phe	Lys	Asp	Leu	Gly	Glu	Glu	Asn	Phe	Lys	10	20
Ala	Leu	Val	Leu	Ile	Ala	Phe	Ala	Gln	Tyr	Leu	Gln	Gln	Cys	Pro	Phe	Glu	Asp	His	Val	30	40
Lys	Leu	Val	Asn	Glu	Val	Thr	Glu	Phe	Ala	Lys	Thr	Cys	Val	Ala	Asp	Glu	Ser	Ala	Glu	50	60
Asn	Cys	Asp	Lys	Ser	Leu	His	Thr	Leu	Phe	Gly	Asp	Lys	Leu	Cys	Thr	Val	Ala	Thr	Leu	70	80
Arg	Glu	Thr	Tyr	Gly	Glu	Met	Ala	Asp	Cys	Cys	Ala	Lys	Gln	Glu	Pro	Glu	Arg	Asn	Glu	90	100
Cys	Phe	Leu	Gln	His	Lys	Asp	Asp	Asn	Pro	Asn	Leu	Pro	Arg	Leu	Val	Arg	Pro	Glu	Val	110	120
Asp	Val	Met	Cys	Thr	Ala	Phe	His	Asp	Asn	Glu	Glu	Thr	Phe	Leu	Lys	Lys	Tyr	Leu	Tyr	130	140
Glu	Ile	Ala	Arg	Arg	His	Pro	Tyr	Phe	Tyr	Ala	Pro	Glu	Leu	Leu	Phe	Phe	Ala	Lys	Arg	150	160
Tyr	Lys	Ala	Ala	Phe	Thr	Glu	Cys	Cys	Gln	Ala	Ala	Asp	Lys	Ala	Ala	Cys	Leu	Leu	Pro	170	180
Lys	Leu	Asp	Glu	Leu	Arg	Asp	Glu	Gly	Lys	Ala	Ser	Ser	Ala	Lys	Gln	Arg	Leu	Lys	Cys	190	200
Ala	Ser	Leu	Gln	Lys	Phe	Gly	Glu	Arg	Ala	Phe	Lys	Ala	Trp	Ala	Val	Ala	Arg	Leu	Ser	210	220
Gln	Arg	Phe	Pro	Lys	Ala	Glu	Phe	Ala	Glu	Val	Ser	Lys	Leu	Val	Thr	Asp	Leu	Thr	Lys	230	240
Val	His	Thr	Glu	Cys	Cys	His	Gly	Asp	Leu	Leu	Glu	Cys	Ala	Asp	Asp	Arg	Ala	Asp	Leu	250	260
Ala	Lys	Tyr	Ile	Cys	Glu	Asn	Gln	Asp	Ser	Ile	Ser	Ser	Lys	Leu	Lys	Glu	Cys	Cys	Glu	270	280
Lys	Pro	Leu	Leu	Glu	Lys	Ser	His	Cys	Ile	Ala	Glu	Val	Glu	Asn	Asp	Glu	Met	Pro	Ala	290	300
Asp	Leu	Pro	Ser	Leu	Ala	Ala	Asp	Phe	Val	Glu	Ser	Lys	Asp	Val	Cys	Lys	Asn	Tyr	Ala	310	320
Glu	Ala	Lys	Asp	Val	Phe	Leu	Gly	Met	Phe	Leu	Tyr	Glu	Tyr	Ala	Arg	Arg	His	Pro	Asp	330	340
Tyr	Ser	Val	Val	Leu	Leu	Leu	Arg	Leu	Ala	Lys	Thr	Tyr	Glu	Thr	Thr	Leu	Glu	Lys	Cys	350	360
Cys	Ala	Ala	Ala	Asp	Pro	His	Glu	Cys	Tyr	Ala	Lys	Val	Phe	Asp	Glu	Phe	Lys	Pro	Leu	370	380
Val	Glu	Glu	Pro	Gln	Asn	Leu	Ile	Lys	Gln	Asn	Cys	Glu	Leu	Phe	Glu	Gln	Leu	Gly	Glu	390	400
Tyr	Lys	Phe	Gln	Asn	Ala	Leu	Leu	Val	Arg	Tyr	Thr	Lys	Lys	Val	Pro	Gln	Val	Ser	Thr	410	420
Pro	Thr	Leu	Val	Glu	Val	Ser	Arg	Asn	Leu	Giv	Lys	Val	Gly	Ser	Lys	Cys	Cys	Lys	His	430	440
Pro	Glu	Ala	Lys	Arg	Met	Pro	Cys	Ala	Glu	Asp	Tyr	Leu	Ser	Val	Val	Leu	Asn	Gln	Leu	450	460
Cys	Val	Leu	His	Glu	Lys	Thr	Pro	Val	Ser	Asp	Arg	Val	Thr	Lys	Cys	Cys	Thr	Glu	Ser	470	480
Leu	Val	Asn	Arg	Arg	Pro	Cys	Phe	Ser	Ala	Leu	Glu	Val	Asp	Glu	Thr	Tyr	Val	Pro	Lys	490	500
Glu	Phe	Asn	Ala	Glu	Thr	Phe	Thr	Phe	His	Ala	Asp	Ile	Cys	Thr	Leu	Ser	Glu	Lys	Glu	510	520
Arg	Gln	Ile	Lys	Lys	Gln	Thr	Ala	Leu	Val	Glu	Leu	Val	Lys	His	Lys	Pro	Lys	Ala	Thr	530	540
Lys	Glu	Gln	Leu	Lys	Ala	Val	Met	Asp	Asp	Phe	Ala	Ala	Phe	Val	Glu	Lys	Cys	Cys	Lys	550	560
Ala	Asp	Asp	Lys	Glu	Thr	Cys	Phe	Ala	Glu	Glu	Gly	Lys	Lys	Leu	Val	Ala	Ala	Ser	Gln	570	580
Ala	Ala	Leu	Giv	Leu																	

```

      10      20      30      40      50      60
GATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAAGAAAATTTCAAA
D A H K S E V A H R F K D L G E E N F K

      70      80      90     100     110     120
GCCTTGGTGGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTTGAAGATCATGTA
A L V L I A F A Q Y L Q Q C P F E D H V

      130     140     150     160     170     180
AAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGATGAGTCAGCTGAA
K L V N E V T E F A K T C V A D E S A E

      190     200     210     220     230     240
AATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACAGTTGCAACTCTT
N C D K S L H T L F G D K L C T V A T L

      250     260     270     280     290     300
CGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCTGAGAGAAATGAA
R E T Y G E M A D C C A K Q E P E R N E

      310     320     330     340     350     360
TGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCGATTGGTGAGACCAGAGGTT
C F L Q H K D D N P N L P R L V R P E V

      370     380     390     400     410     420
GATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTGA AAAAATACTTATAT
D V M C T A F H D N E E T F L K K Y L Y

      430     440     450     460     470     480
GAAATTGCCAGAAGACATCCTTACTTTTATGCCCGGAACCTCTTTTCTTTGCTAAAAGG
E I A R R H P Y F Y A P E L L F F A K R

      490     500     510     520     530     540
TATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCCTGCCTGTTGCCA
Y K A A F T E C C Q A A D K A A C L L P

      550     560     570     580     590     600
AAGCTCGATGAACCTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAGAGACTCAAATGT
K L D E L R D E G K A S S A K Q R L K C

      610     620     630     640     650     660
GCCAGTCTCCAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTGGCTCGCCTGAGC
A S L Q K F G E R A F K A W A V A R L S

      670     680     690     700     710     720
CAGAGATTTCCCAAAGCTGAGTTTGAGAAAGTTTCCAAGTTAGTGACAGATCTTACCAA
Q R F P K A E F A E V S K L V T D L T K

      730     740     750     760     770     780
GTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGACAGGGCGGACCTT
V H T E C C H G D L L E C A D D R A D L

      790     800     810     820     830     840
GCCAAGTATATCTGTGAAAATCAGGATTGATCTCCAGTAAACTGAAGGAATGCTGTGAA
A K Y I C E N Q D S I S S K L K E C C E

      850     860     870     880     890     900
AAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGATGAGATGCCTGCT
K P L L E K S H C I A E V E N D E M P A

```

Figure 2 DNA sequence coding for mature HSA

910 920 930 940 950 960  
GACTTGCCTTCATTAGCTGCTGATTTTGTGGAAAGTAAGGATGTTTGCAAAAACCTATGCT  
D L P S L A A D F V E S K D V C K N Y A

970 980 990 1000 1010 1020  
GAGGCAAAAGGATGTCTTCCTGGGCATGTTTTGTATGAATATGCAAGAAGGCATCCTGAT  
E A K D V F L G M F L Y E Y A R R H P D

1030 1040 1050 1060 1070 1080  
TACTCTGCTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACTCTAGAGAAGTGCT  
Y S V V L L L R L A K T Y E T T L E K C

1090 1100 1110 1120 1130 1140  
TGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTGATGAATTTAAACCTCTT  
C A A A D P H E C Y A K V F D E F K P L

1150 1160 1170 1180 1190 1200  
GTGGAAAGAGCCTCAGAATTTAATCAAAACAAACTGTGAGCTTTTTGAGCAGCTTGGAGAG  
V E E P Q N L I K Q N C E L F E Q L G E

1210 1220 1230 1240 1250 1260  
TACAAATTCAGAATGCGCTATTAGTTGTTACACCAAGAAAGTACCCCAAGTGCTCAACT  
Y K F Q N A L L V R Y T K K V P Q V S T

1270 1280 1290 1300 1310 1320  
CCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAATGTTGTAAACAT  
P T L V E V S R N L G K V G S K C C K H

1330 1340 1350 1360 1370 1380  
CCTGAAGCAAAAAGAAATGCCCTGTGCAGAAAGACTATCTATCCGTGGTCCTGAACCAAGTTA  
P E A K R M P C A E D Y L S V V L N Q L

1390 1400 1410 1420 1430 1440  
TGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACAAAATGCTGCACAGAGTCC  
C V L H E K T P V S D R V T K C C T E S

1450 1460 1470 1480 1490 1500  
TTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACATACGTTCCCAAA  
L V N R R P C F S A L E V D E T Y V P K

1510 1520 1530 1540 1550 1560  
GAGTTTAATGCTGAAACATTACCTTCCATGCAGATATATGCACACTTTCTGAGAAGGAG  
E F N A E T F T F H A D I C T L S E K E

1570 1580 1590 1600 1610 1620  
AGACAAATCAAGAAACAAACTGCACCTTGTGAGCTTGTGAAACACAAGCCCCAAGGCAACA  
R Q I K K Q T A L V E L V K H K P K A T

1630 1640 1650 1660 1670 1680  
AAAGAGCAACTGAAAGCTGTTATGGATGATTTTCGAGCTTTTGTAGAGAAGTGCTGCAAG  
K E Q L K A V M D D F A A F V E K C C K

1690 1700 1710 1720 1730 1740  
GCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTGCTGCAAGTCAA  
A D D K E T C F A E E G K K L V A A S Q

1750 1760 1770 1780  
GCTGCCTTAGGCTTATAACATCTACATTTAAAGCATCTCAG  
A A L G L

Figure 2. cont'd.




Figure 3 Construction of mHOBI6.




Figure 4 Construction of pHOB31.






FIGURE 5

Rocket immunoelectrophoretic analysis of culture supernatant from S.cerevisae AH22 transformants obtained with a plasmid containing the complete HSA coding region (samples 1-4) and from transformants harbouring an equivalent plasmid encoding truncated HSA (1-389) (samples 5-8).




Figure 1 Construction of pDBD3






Figure 8. Construction of pDBD4

Titration of bilirubin by BPL HSA and D2L

(Measurement of fluorescence enhancement)







**THIS PAGE BLANK (USPTO)**